Lopid and Senna drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lopid (gemfibrozil) and Senna (senna). Common drug interactions include bone density decreased among females and gastrointestinal haemorrhage among males.

The phase IV clinical study analyzes what interactions people have when they take Lopid and Senna. It is created by eHealthMe based on reports of 27 people who take the same drugs from the FDA, and is updated regularly.

What is Lopid?

Lopid has active ingredients of gemfibrozil. It is often used in high blood cholesterol. eHealthMe is studying from 9,700 Lopid users. Check the latest studies of Lopid.

What is Senna?

Senna has active ingredients of senna. It is often used in constipation. eHealthMe is studying from 37,302 Senna users. Check the latest studies of Senna.



On Aug, 05, 2026

27 people who take Lopid and Senna together, and have interactions are studied.

Lopid and Senna drug interactions.

What are the common drug interactions of Lopid and Senna, by gender? *:

female:

  1. Bone density decreased
  2. Death
  3. Emotional distress
  4. Tooth loss
  5. Anuria (failure of the kidneys to produce urine)
  6. Chills (felling of cold)
  7. Dysuria (painful or difficult urination)
  8. Flank pain (a distressing sensation experienced around the lower back and the upper abdomen)
  9. Insomnia (sleeplessness)
  10. Palpitations (feelings or sensations that your heart is pounding or racing)

male:

  1. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  2. Anxiety
  3. Tooth fracture
  4. Asthma
  5. Atelectasis (partial or complete collapse of the lung)
  6. Calculus urinary (stone in urinary system)
  7. Cauda equina syndrome (affecting the bundle of nerve roots)
  8. Diabetic foot
  9. Dyslipidaemia (abnormal amount of lipids)
  10. Hepatic steatosis (fatty liver disease)

What are the common drug interactions of Lopid and Senna, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Death
  2. Disturbance in attention
  3. Dizziness
  4. Epistaxis (bleed from the nose)
  5. Feeling hot
  6. Flushing (the warm, red condition of human skin)
  7. Headache (pain in head)
  8. Heart rate increased
  9. Hyperhidrosis (abnormally increased sweating)
  10. Loss of consciousness

50-59:

  1. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  2. Hypersomnia (excessive daytime sleepiness (eds))
  3. Injury
  4. Localised infection (infection at the single location)
  5. Myelopathy (any neurologic deficit related to the spinal cord)
  6. Pneumonia
  7. Pyrexia (fever)
  8. Sleep disorder
  9. Abdominal hernia
  10. Aspartate aminotransferase increased

60+:

  1. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  2. Pneumonia
  3. Pyelonephritis (inflammation of kidney caused by bacteria)
  4. Renal pain (kidney pain)
  5. Urinary tract infection
  6. Abdominal pain
  7. Acute respiratory failure
  8. Anaemia (lack of blood)
  9. Asthenia (weakness)
  10. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)

What are the existing conditions these people have? *

  1. High Blood Pressure: 4 people, 14.81%
  2. Pain: 4 people, 14.81%
  3. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 11.11%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 11.11%
  5. Type 2 Diabetes: 3 people, 11.11%
  6. Metabolic Disorder (an abnormal function and pattern of body fat. insulin resistance refers to the diminished ability of cells to respond to the action of insulin in promoting the transport of the sugar glucose, from blood into muscles and other tissues): 2 people, 7.41%
  7. Insomnia (sleeplessness): 2 people, 7.41%
  8. Hypersensitivity: 2 people, 7.41%
  9. Hiv Infection: 2 people, 7.41%
  10. Nausea (feeling of having an urge to vomit): 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Lopid and Senna?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lopid and Senna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lopid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Senna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lopid and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Senna and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gemfibrozil and senna (the active ingredients of Lopid and Senna, respectively), and Lopid and Senna (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: